Combination therapy of anti-CD20 antibody with Bcl-2 inhibitor and MDM2 inhibitor

• 收藏
• 分享

专利权人:

F. HOFFMANN-LA ROCHE AG

发明人:

KLEIN, Christian,HERTING, Frank,DANGL, Markus

申请号：

PE2017002462

公开号：

PE20184542A1

申请日:

2016.05.23

申请国别(地区):

PE

年份:

2018

代理人:

摘要：

This is an anti-CD20 antibody that combines with Bcl-2 inhibitors and MDM2 inhibitors to treat cancer. The antibody is the first unstitched anti-CD20 antibody or a humanized b-ly1 antibody This antibody is mainly used for the comprehensive treatment of cancer with the hallucinogenic agent CD20, such as lymphoma or lymphocytic leukemia.Referido a un anticuerpo anti-CD20 en combinacion con un inhibidor de Bcl-2 y un inhibidor de MDM2 para el tratamiento del cancer. Dicho anticuerpo es un anticuerpo anti-CD20 de tipo I no fucosilado, o un anticuerpo B-Ly1 humanizado. Este anticuerpo es utilizado especialmente a la terapia combinada de canceres que expresan CD20, como linfoma o leucemia linfocitica.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/